MEP4108A - Perforisane mikročestice i postupci za njihovu primjenu - Google Patents
Perforisane mikročestice i postupci za njihovu primjenuInfo
- Publication number
- MEP4108A MEP4108A MEP-41/08A MEP4108A MEP4108A ME P4108 A MEP4108 A ME P4108A ME P4108 A MEP4108 A ME P4108A ME P4108 A MEP4108 A ME P4108A
- Authority
- ME
- Montenegro
- Prior art keywords
- particles
- methods
- perforated microparticles
- microparticles
- perforated
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/906—Drug delivery
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/926—Topical chemical, e.g. cosmetic or sunscreen
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pulmonology (AREA)
- Otolaryngology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Nanotechnology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Anesthesiology (AREA)
- Diabetes (AREA)
- Dispersion Chemistry (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Physics & Mathematics (AREA)
- Pain & Pain Management (AREA)
- Optics & Photonics (AREA)
Abstract
Date su tehnički proizvedene čestice za davanje nekog bioaktivnog sredstva u respiratorni trakt pacijenta. Čestice se mogu upotrebljavati u obliku suvog praška ili u obliku stabilisanih disperzija u vidu nevodene kontinualne faze. Kod posebno preporučljivih izvodjenja čestice se mogu koristiti pomoću inhalacionog uredjaja, kao što je inhalator suvog praška, inhalator izmjerenih doza ili zamagljivač.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US6033797P | 1997-09-29 | 1997-09-29 | |
US10693298A | 1998-06-29 | 1998-06-29 | |
US13384898A | 1998-08-14 | 1998-08-14 | |
PCT/US1998/020602 WO1999016419A1 (en) | 1997-09-29 | 1998-09-29 | Perforated microparticles and methods of use |
Publications (1)
Publication Number | Publication Date |
---|---|
MEP4108A true MEP4108A (xx) | 2010-02-10 |
Family
ID=27369827
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MEP-41/08A MEP4108A (xx) | 1997-09-29 | 1998-09-29 | Perforisane mikročestice i postupci za njihovu primjenu |
Country Status (28)
Country | Link |
---|---|
EP (4) | EP1019021B2 (bs) |
JP (9) | JP2003525842A (bs) |
KR (4) | KR100599634B1 (bs) |
CN (1) | CN1169520C (bs) |
AT (3) | ATE238035T1 (bs) |
AU (4) | AU756693B2 (bs) |
BG (1) | BG64816B1 (bs) |
BR (1) | BR9812693A (bs) |
CA (4) | CA2304973C (bs) |
CZ (1) | CZ300758B6 (bs) |
DE (2) | DE69813853T3 (bs) |
DK (2) | DK1019021T4 (bs) |
EA (2) | EA002562B1 (bs) |
EE (1) | EE04628B1 (bs) |
ES (3) | ES2205560T5 (bs) |
HK (1) | HK1031680A1 (bs) |
HR (1) | HRP20000175B1 (bs) |
IL (2) | IL135126A0 (bs) |
IS (1) | IS2154B (bs) |
ME (1) | MEP4108A (bs) |
NO (1) | NO340149B1 (bs) |
NZ (1) | NZ503464A (bs) |
PL (1) | PL195212B1 (bs) |
PT (1) | PT1019022E (bs) |
RS (1) | RS50182B (bs) |
SK (1) | SK285068B6 (bs) |
TR (1) | TR200000819T2 (bs) |
WO (3) | WO1999016422A1 (bs) |
Families Citing this family (234)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6503480B1 (en) | 1997-05-23 | 2003-01-07 | Massachusetts Institute Of Technology | Aerodynamically light particles for pulmonary drug delivery |
US6254854B1 (en) | 1996-05-24 | 2001-07-03 | The Penn Research Foundation | Porous particles for deep lung delivery |
AU756693B2 (en) * | 1997-09-29 | 2003-01-23 | Novartis Ag | Stabilized bioactive preparations and methods of use |
US6433040B1 (en) | 1997-09-29 | 2002-08-13 | Inhale Therapeutic Systems, Inc. | Stabilized bioactive preparations and methods of use |
US20060165606A1 (en) | 1997-09-29 | 2006-07-27 | Nektar Therapeutics | Pulmonary delivery particles comprising water insoluble or crystalline active agents |
US6946117B1 (en) * | 1997-09-29 | 2005-09-20 | Nektar Therapeutics | Stabilized preparations for use in nebulizers |
GB9727102D0 (en) * | 1997-12-22 | 1998-02-25 | Andaris Ltd | Microparticles and their therapeutic use |
KR100796220B1 (ko) * | 1998-06-29 | 2008-01-21 | 넥타르 테라퓨틱스 | 미립자 전달 시스템 및 사용 방법 |
WO2000000215A1 (en) * | 1998-06-29 | 2000-01-06 | Inhale Therapeutic Systems, Inc. | Particulate delivery systems and methods of use |
US6630169B1 (en) | 1999-03-31 | 2003-10-07 | Nektar Therapeutics | Particulate delivery systems and methods of use |
US6223455B1 (en) † | 1999-05-03 | 2001-05-01 | Acusphere, Inc. | Spray drying apparatus and methods of use |
NZ516083A (en) * | 1999-05-27 | 2003-08-29 | Acusphere Inc | Porous drug matrices and methods of manufacture thereof |
US6630121B1 (en) | 1999-06-09 | 2003-10-07 | The Regents Of The University Of Colorado | Supercritical fluid-assisted nebulization and bubble drying |
US6858199B1 (en) | 2000-06-09 | 2005-02-22 | Advanced Inhalation Research, Inc. | High efficient delivery of a large therapeutic mass aerosol |
US6586008B1 (en) * | 1999-08-25 | 2003-07-01 | Advanced Inhalation Research, Inc. | Use of simple amino acids to form porous particles during spray drying |
JP2003507410A (ja) * | 1999-08-25 | 2003-02-25 | アドバンスト インハレーション リサーチ,インコーポレイテッド | 乾燥粉末製剤からの放出調節 |
AU2729101A (en) | 1999-12-21 | 2001-07-03 | Rxkinetix, Inc. | Particulate drug-containing products and method of manufacture |
US6761909B1 (en) | 1999-12-21 | 2004-07-13 | Rxkinetix, Inc. | Particulate insulin-containing products and method of manufacture |
GB0003935D0 (en) * | 2000-02-08 | 2000-04-12 | King S College London | Formulation for dry powder inhaler |
EP1263605B1 (en) | 2000-02-08 | 2005-09-14 | 3M Innovative Properties Company | Improved methods for cold image transfer |
JP2003522304A (ja) | 2000-02-08 | 2003-07-22 | スリーエム イノベイティブ プロパティズ カンパニー | インク定着材料およびインク定着方法 |
US8404217B2 (en) | 2000-05-10 | 2013-03-26 | Novartis Ag | Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use |
US7871598B1 (en) | 2000-05-10 | 2011-01-18 | Novartis Ag | Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use |
WO2001085136A2 (en) | 2000-05-10 | 2001-11-15 | Alliance Pharmaceutical Corporation | Phospholipid-based powders for drug delivery |
WO2001087277A2 (en) * | 2000-05-15 | 2001-11-22 | Vectura Limited | Method of manufacturing particles |
NZ523693A (en) * | 2000-07-10 | 2004-08-27 | Chiron Corp | Macrolide formulations for inhalation and methods of treatment of endobronchial infections |
US7141236B2 (en) | 2000-07-28 | 2006-11-28 | Nektar Therapeutics | Methods and compositions for delivering macromolecules to or via the respiratory tract |
DE10064219B9 (de) * | 2000-12-22 | 2009-02-12 | Nasalis Pain Relief International Gmbh | Neue Fentanyl und/oder dessen Derivate enthaltende pharmazeutische Zusammensetzung zur nasalen Anwendung |
US20030072717A1 (en) | 2001-02-23 | 2003-04-17 | Vapotronics, Inc. | Inhalation device having an optimized air flow path |
GB0106403D0 (en) * | 2001-03-15 | 2001-05-02 | Pharmaceutical Profiles | Labelling of dry powder formulations for inhalation |
GB0107106D0 (en) * | 2001-03-21 | 2001-05-09 | Boehringer Ingelheim Pharma | Powder inhaler formulations |
EP1390012A4 (en) * | 2001-04-26 | 2009-10-28 | Novartis Ag | NEW METHODS AND COMPOSITIONS FOR RELEASING MACROMOLECULES TO OR BY THE AIRWAY |
US7905230B2 (en) | 2001-05-09 | 2011-03-15 | Novartis Ag | Metered dose inhaler with lockout |
CN1236831C (zh) * | 2001-05-21 | 2006-01-18 | 茵捷特数码浮质有限公司 | 用于经肺部途径递送蛋白质的组合物 |
ATE415155T1 (de) | 2001-05-24 | 2008-12-15 | Alexza Pharmaceuticals Inc | Verabreichung von alprazolam, estazolam, midazolam oder triazolam durch inhalation |
US7766013B2 (en) | 2001-06-05 | 2010-08-03 | Alexza Pharmaceuticals, Inc. | Aerosol generating method and device |
US6805853B2 (en) | 2001-11-09 | 2004-10-19 | Alexza Molecular Delivery Corporation | Delivery of diazepam through an inhalation route |
EP1392262A1 (en) | 2001-05-24 | 2004-03-03 | Alexza Molecular Delivery Corporation | Delivery of drug esters through an inhalation route |
WO2002094242A1 (en) | 2001-05-24 | 2002-11-28 | Alexza Molecular Delivery Corporation | Delivery of rizatriptan or zolmitriptan through an inhalation route |
US20070122353A1 (en) | 2001-05-24 | 2007-05-31 | Hale Ron L | Drug condensation aerosols and kits |
JP2004531333A (ja) | 2001-06-20 | 2004-10-14 | ネクター セラピューティクス | 粉末エアロゾル化装置及び方法 |
US8337816B2 (en) * | 2001-09-17 | 2012-12-25 | Glaxo Group Limited | Dry powder medicament formulations |
ATE401058T1 (de) | 2001-11-01 | 2008-08-15 | Nektar Therapeutics | Sprühtrocknungsverfahren |
EP1446102A1 (en) | 2001-11-21 | 2004-08-18 | Alexza Molecular Delivery Corporation | Delivery of caffeine through an inhalation route |
EP1458360B1 (en) | 2001-12-19 | 2011-05-11 | Novartis AG | Pulmonary delivery of aminoglycosides |
AU2002351271A1 (en) | 2001-12-21 | 2003-07-24 | Nektar Therapeutics | Capsule package with moisture barrier |
CN1642533A (zh) * | 2002-03-18 | 2005-07-20 | 山之内制药株式会社 | 吸入用粉末医药组合物及其制备方法 |
US7008644B2 (en) | 2002-03-20 | 2006-03-07 | Advanced Inhalation Research, Inc. | Method and apparatus for producing dry particles |
US9339459B2 (en) | 2003-04-24 | 2016-05-17 | Nektar Therapeutics | Particulate materials |
US6941980B2 (en) | 2002-06-27 | 2005-09-13 | Nektar Therapeutics | Apparatus and method for filling a receptacle with powder |
MY142204A (en) | 2002-07-25 | 2010-10-29 | Pharmacia Corp | Pramipexole once-daily dosage form |
CN1694689A (zh) * | 2002-09-30 | 2005-11-09 | 阿库斯菲尔公司 | 供吸入的缓释多孔微粒 |
US7516741B2 (en) | 2002-12-06 | 2009-04-14 | Novartis Ag | Aerosolization apparatus with feedback mechanism |
WO2004054556A1 (en) * | 2002-12-13 | 2004-07-01 | Adagit | Pharmaceutical porous particles |
US7731947B2 (en) | 2003-11-17 | 2010-06-08 | Intarcia Therapeutics, Inc. | Composition and dosage form comprising an interferon particle formulation and suspending vehicle |
KR20050095838A (ko) * | 2002-12-31 | 2005-10-04 | 넥타르 테라퓨틱스 | 폐 투여용 불용성 활성제를 갖는 약제학적 제형물 |
US7669596B2 (en) | 2002-12-31 | 2010-03-02 | Novartis Pharma Ag | Aerosolization apparatus with rotating capsule |
US7638138B2 (en) | 2003-02-21 | 2009-12-29 | Translational Research, Ltd. | Compositions for nasal administration of pharmaceuticals |
US8765124B2 (en) | 2003-02-28 | 2014-07-01 | Chugai Seiyaku Kabushiki Kaisha | Stabilized preparation containing protein |
EP1607117A4 (en) | 2003-03-27 | 2007-10-24 | Bioactis Ltd | APPLICATOR FOR POWDER MEDICATION IN THE NOSE CAVE |
US8869794B1 (en) | 2003-04-09 | 2014-10-28 | Novartis Pharma Ag | Aerosolization apparatus with capsule puncturing member |
MXPA05010842A (es) | 2003-04-09 | 2006-03-30 | Nektar Therapeutics | Aparato de nebulizacion con protector de entrada de aire. |
US10207066B2 (en) | 2003-04-09 | 2019-02-19 | Bgp Products Operations Gmbh | Aerosolization apparatus with capsule puncture alignment guide |
EP1625334B9 (en) | 2003-05-21 | 2012-07-25 | Alexza Pharmaceuticals, Inc. | Percussively ignited self-contained heating unit |
AU2004251623B2 (en) | 2003-05-28 | 2010-03-18 | Novartis Ag | Spray drying of an alcoholic aqueous solution for the manufacture of a water-in-soluble active agentmicroparticle with a partial or complete amino acid and/or phospholipid coat |
CN1856296A (zh) * | 2003-09-30 | 2006-11-01 | 阿库斯菲尔公司 | 可注射的、口服、或局部用缓释药物制剂 |
US7621299B2 (en) | 2003-10-03 | 2009-11-24 | Cabot Corporation | Method and apparatus for filling a vessel with particulate matter |
CA2543296A1 (en) * | 2003-10-31 | 2005-05-12 | Point Biomedical Corporation | Reconstitutable microsphere compositions useful as ultrasonic contrast agents |
EP1701714A2 (en) | 2004-01-07 | 2006-09-20 | Nektar Therapeutics | Improved sustained release compositions for pulmonary administration of insulin |
KR20070009639A (ko) * | 2004-04-13 | 2007-01-18 | 캠브리지 바이오스테빌리티 리미티드 | 부유 유리 입자를 함유한 액체 |
ITMI20040795A1 (it) * | 2004-04-23 | 2004-07-23 | Eratech S R L | Composizione farmaceutica solida secca suo processo di preparazione e sospensione acquosa stabile ottenuta dalla stessa |
US8012457B2 (en) | 2004-06-04 | 2011-09-06 | Acusphere, Inc. | Ultrasound contrast agent dosage formulation |
MXPA06015220A (es) | 2004-06-21 | 2007-12-13 | Nektar Therapeutics | Composiciones comprendiendo anfotericina b, metodos y sistemas. |
US8513204B2 (en) | 2004-06-21 | 2013-08-20 | Novartis Ag | Compositions comprising amphotericin B, mehods and systems |
EP1785145A4 (en) | 2004-08-10 | 2008-08-13 | Translational Res Ltd | TRANSNASAL COMPOSITION WITH IMMEDIATE EFFECT AND HIGH RESORBIBILITY |
CN101843597A (zh) | 2004-08-13 | 2010-09-29 | 贝林格尔·英格海姆国际有限公司 | 包含普拉克索或其可药用盐的延长释放小球制剂、其制备方法及其用途 |
SI1781260T2 (sl) | 2004-08-13 | 2014-08-29 | Boehringer Ingelheim International Gmbh | Tabletna formulacija s podaljšanim sproščanjem, ki vsebuje pramipeksol ali njegovo farmacevtsko sprejemljivo sol, postopek za izdelavo le-te in njena uporaba |
US11246913B2 (en) | 2005-02-03 | 2022-02-15 | Intarcia Therapeutics, Inc. | Suspension formulation comprising an insulinotropic peptide |
WO2006083761A2 (en) | 2005-02-03 | 2006-08-10 | Alza Corporation | Solvent/polymer solutions as suspension vehicles |
MX2007011772A (es) * | 2005-03-23 | 2007-12-05 | Elan Pharma Int Ltd | Formulaciones de antihistaminico y corticosteroide de materia en nanoparticulas. |
PE20061324A1 (es) | 2005-04-29 | 2007-01-15 | Centocor Inc | Anticuerpos anti-il-6, composiciones, metodos y usos |
WO2006124446A2 (en) * | 2005-05-12 | 2006-11-23 | Nektar Therapeutics | Sustained release microparticles for pulmonary delivery |
KR101348594B1 (ko) | 2005-05-18 | 2014-01-07 | 노바르티스 아게 | 기관지 치료를 위한 밸브, 장치 및 방법 |
TW200716174A (en) | 2005-05-19 | 2007-05-01 | Centocor Inc | Anti-MCP-1 antibodies, compositions, methods and uses |
ES2710289T3 (es) | 2005-06-30 | 2019-04-24 | Janssen Biotech Inc | Anticuerpos anti-IL-23, composiciones, procedimientos y usos |
ITMI20051999A1 (it) | 2005-10-21 | 2007-04-22 | Eratech S R L | Formulazioni inalatorie di farmaci in fora di polvere secca per somministrazione come tale o con nebulizzatore e dotate di elevata erogabilita' respirabilita' e stabilita' |
JP5113328B2 (ja) * | 2005-11-07 | 2013-01-09 | 田辺三菱製薬株式会社 | エマルション並びにそれを用いた目的物質粒子の製造方法及び医薬品 |
US8293869B2 (en) | 2005-12-16 | 2012-10-23 | Nektar Therapeutics | Polymer conjugates of GLP-1 |
RS60616B1 (sr) | 2005-12-29 | 2020-09-30 | Janssen Biotech Inc | Humana anti-il-23 antitela, kompozicije, postupci i upotrebe |
JP2009524646A (ja) * | 2006-01-27 | 2009-07-02 | ザ・プロヴォスト,フェローズ・アンド・スカラーズ・オブ・ザ・カレッジ・オブ・ザ・ホーリー・アンド・アンディヴァイデッド・トリニティー・オブ・クイーン・エリザベス,ニア・ダブリン | 多孔性微粒子の製造方法 |
AU2007266475B2 (en) | 2006-05-30 | 2009-12-03 | Intarcia Therapeutics, Inc. | Two-piece, internal-channel osmotic delivery system flow modulator |
AU2007284759B2 (en) | 2006-08-09 | 2010-10-28 | Intarcia Therapeutics, Inc. | Osmotic delivery systems and piston assemblies |
JP5415769B2 (ja) * | 2006-12-26 | 2014-02-12 | 株式会社新日本科学 | 経鼻投与用製剤 |
ES2594867T3 (es) | 2007-03-09 | 2016-12-23 | Alexza Pharmaceuticals, Inc. | Unidad de calentamiento para usar en un dispositivo de administración de fármaco |
CN105688191A (zh) | 2007-04-23 | 2016-06-22 | 精达制药公司 | 促胰岛素释放肽的混悬制剂及其应用 |
WO2009023803A2 (en) * | 2007-08-15 | 2009-02-19 | Abbott Respiratory Llc | Modulated release formulation for the delivery of one or more medicaments |
DK2240155T3 (da) | 2008-02-13 | 2012-09-17 | Intarcia Therapeutics Inc | Indretninger, formuleringer og fremgangsmåder til levering af flere gavnlige midler |
WO2009120619A2 (en) * | 2008-03-24 | 2009-10-01 | Novartis Ag | Nuclease compositions, methods of making and using such compositions, and systems for pulmonary delivery of such compositions |
PL220269B1 (pl) | 2008-04-21 | 2015-09-30 | Przedsiębiorstwo Produkcji Farmaceutycznej Hasco Lek Spółka Akcyjna | Kompozytowy nośnik leków proszkowych, sposób wytwarzania nośnika leków oraz urządzenie do wytwarzania cząstek nośnika kompozytowego |
WO2009140587A1 (en) | 2008-05-15 | 2009-11-19 | Novartis Ag | Pulmonary delivery of a fluoroquinolone |
EP2350118B1 (en) | 2008-09-19 | 2016-03-30 | Nektar Therapeutics | Carbohydrate-based drug delivery polymers and conjugates thereof |
PL2356269T3 (pl) | 2008-10-31 | 2016-12-30 | Kompozycje białek rusztowania oparte na domenie fibronektyny typu III, sposoby i zastosowania | |
NZ592861A (en) * | 2008-11-04 | 2013-01-25 | Cipla Ltd | Pharmaceutical aerosol composition |
US9925282B2 (en) | 2009-01-29 | 2018-03-27 | The General Hospital Corporation | Cromolyn derivatives and related methods of imaging and treatment |
DK2396011T3 (en) | 2009-02-12 | 2016-04-25 | Janssen Biotech Inc | Fibronectin TYPE III DOMAIN-BASED SCAFFOLD COMPOSITIONS, METHODS AND USES |
EP2221048A1 (en) | 2009-02-18 | 2010-08-25 | Siegfried Generics International AG | Pharmaceutical composition for inhalation |
EP2413902B1 (en) | 2009-03-18 | 2019-07-17 | Incarda Therapeutics, Inc. | Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration |
CN102497853B (zh) | 2009-03-26 | 2018-03-23 | 普马特里克斯营业公司 | 治疗肺病的干粉配方与方法 |
GB0908129D0 (en) * | 2009-05-12 | 2009-06-24 | Innovata Ltd | Composition |
KR20100123240A (ko) * | 2009-05-15 | 2010-11-24 | 포항공과대학교 산학협력단 | 호흡기 염증성 질환의 치료 또는 예방을 위한 호흡기내 투여용 약학 제제 및 상기 질환의 치료 또는 예방 방법 |
EP2429495A4 (en) | 2009-05-15 | 2014-01-22 | Shin Nippon Biomedical Lab Ltd | INTRANASAL PHARMACEUTICAL COMPOSITIONS WITH ENHANCED PHARMACOKINETICS |
DK2435024T3 (en) | 2009-05-29 | 2016-10-24 | Pearl Therapeutics Inc | Compositions for the respiratory delivery of active agents and related methods and systems |
US8815258B2 (en) | 2009-05-29 | 2014-08-26 | Pearl Therapeutics, Inc. | Compositions, methods and systems for respiratory delivery of two or more active agents |
WO2011013003A2 (en) | 2009-07-31 | 2011-02-03 | Shin Nippon Biomedical Laboratories, Ltd. | Intranasal granisetron and nasal applicator |
MX352878B (es) | 2009-09-28 | 2017-12-13 | Intarcia Therapeutics Inc | Establecimiento y/o terminacion rapidos de suministro de estado estable sustancial de farmaco. |
CN102811715A (zh) * | 2009-12-08 | 2012-12-05 | 悉尼大学 | 可吸入制剂 |
EP2464346A1 (en) | 2010-08-30 | 2012-06-20 | Pulmatrix, Inc. | Treatment of cystic fibrosis using calcium lactate, leucine and sodium chloride in a respiraple dry powder |
EP2611438B1 (en) | 2010-08-30 | 2020-04-01 | Pulmatrix Operating Company, Inc. | Dry powder formulations and methods for treating pulmonary diseases |
DK2621488T3 (en) | 2010-09-29 | 2019-03-04 | Pulmatrix Operating Co Inc | CATIONIC DRY POWDER |
RU2017144619A (ru) | 2010-09-29 | 2019-02-20 | Пулмэтрикс, Инк. | Катионы одновалентных металлов сухих порошков для ингаляций |
CN103228266B (zh) * | 2010-10-29 | 2017-11-14 | 健康科学西部大学 | 三元混合物制剂 |
US20120208755A1 (en) | 2011-02-16 | 2012-08-16 | Intarcia Therapeutics, Inc. | Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers |
EP2678305A4 (en) * | 2011-02-25 | 2015-11-04 | Univ Johns Hopkins | CHALCONE DERIVATIVES AS NRF2 ACTIVATORS |
GB201108039D0 (en) | 2011-05-13 | 2011-06-29 | Mexichem Amanco Holding Sa | Compositions |
SG194896A1 (en) * | 2011-05-17 | 2013-12-30 | Pearl Therapeutics Inc | Compositions, methods & systems for respiratory delivery of two or more active agents |
GB201117619D0 (en) | 2011-10-12 | 2011-11-23 | Mexichem Amanco Holding Sa | Compositions |
GB201117621D0 (en) * | 2011-10-12 | 2011-11-23 | Mexichem Amanco Holding Sa | Compositions |
EP2601941A1 (en) | 2011-12-06 | 2013-06-12 | Ludwig-Maximilians-Universität München | Beta-O/S/N fatty acid based compounds as antibacterial and antiprotozoal agents |
US9763965B2 (en) | 2012-04-13 | 2017-09-19 | Glaxosmithkline Intellectual Property Development Limited | Aggregate particles |
WO2014066318A1 (en) | 2012-10-25 | 2014-05-01 | The General Hospital Corporation | Combination therapies for the treatment of alzheimer's disease and related disorders |
US20140275517A1 (en) | 2013-03-15 | 2014-09-18 | Pearl Therapeutics, Inc. | Methods and systems for conditioning of particulate crystalline materials |
GB201306984D0 (en) * | 2013-04-17 | 2013-05-29 | Mexichem Amanco Holding Sa | Composition |
EP3607941A1 (en) | 2013-04-30 | 2020-02-12 | Otitopic Inc. | Dry powder formulations and methods of use |
KR101543507B1 (ko) * | 2013-05-15 | 2015-08-11 | 씨제이헬스케어 주식회사 | 연속 공정의 미립구의 제조 방법 및 이로부터 제조된 미립구 |
CA2913235C (en) * | 2013-05-23 | 2021-07-13 | Aztherapies, Inc. | Methods for delivering cromolyn |
US10525005B2 (en) | 2013-05-23 | 2020-01-07 | The General Hospital Corporation | Cromolyn compositions and methods thereof |
WO2014207213A1 (en) | 2013-06-28 | 2014-12-31 | Medizinische Universität Innsbruck | Novel inhibitors of protein kinase c epsilon signaling |
CA2928028A1 (en) | 2013-10-22 | 2015-04-30 | The General Hospital Corporation | Cromolyn derivatives and related methods of imaging and treatment |
US20150224077A1 (en) | 2014-02-10 | 2015-08-13 | Patara Pharma, LLC | Methods for the Treatment of Systemic Disorders Treatable with Mast Cell Stabilizers, including Mast Cell Related Disorders |
EP3725311A1 (en) | 2014-02-10 | 2020-10-21 | Respivant Sciences GmbH | Methods for the treatment of lung diseases with mast cell stabilizers |
JP6701086B2 (ja) | 2014-02-20 | 2020-05-27 | オティトピック インコーポレイテッド | 吸入用の乾燥粉末製剤 |
EP2947460A1 (en) | 2014-05-22 | 2015-11-25 | Medizinische Universität Wien | Personalized therapy of inflammation-associated cancer using methods of assessing the susceptibility of a subject to the treatment with EGFR inhibitors/antagonists |
JP6850524B2 (ja) | 2014-07-31 | 2021-03-31 | オティトピック インク. | 吸入用の乾燥粉末製剤 |
US9889085B1 (en) | 2014-09-30 | 2018-02-13 | Intarcia Therapeutics, Inc. | Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c |
MX2017005692A (es) | 2014-10-31 | 2017-08-07 | Glaxosmithkline Ip Dev Ltd | Formulacion en polvo. |
JP6395216B2 (ja) * | 2014-11-13 | 2018-09-26 | 国立大学法人大阪大学 | 液体に含まれる超微細バブルの測定方法及びその測定装置 |
GB2542064B (en) | 2015-01-20 | 2020-11-18 | Univ California | Unit aerosol doses for anticoagulation |
WO2016135140A1 (en) | 2015-02-23 | 2016-09-01 | Cemm - Forschungszentrum Für Molekulare Medizin Gmbh | 4-aminoquinazoline derivatives as mth1 inhibitors for the therapy of cancer |
WO2016135138A1 (en) | 2015-02-23 | 2016-09-01 | Cemm - Forschungszentrum Für Molekulare Medizin Gmbh | Oxoquinoline derivatives as mth1 inhibitors for the therapy of cancer |
WO2016135139A1 (en) | 2015-02-23 | 2016-09-01 | Cemm - Forschungszentrum Für Molekulare Medizin Gmbh | 2,3-dihydrocyclopenta[b]quinoline derivatives as mth1 inhibitors for the therapy of cancer |
WO2016135137A1 (en) | 2015-02-23 | 2016-09-01 | Cemm - Forschungszentrum Für Molekulare Medizin Gmbh | Substituted 4-(phenylamino)quinoline derivatives as mth1 inhibitors for the therapy of cancer |
WO2016170102A1 (en) | 2015-04-22 | 2016-10-27 | Cemm - Forschungszentrum Für Molekulare Medizin Gmbh | Combination of an antiandrogen with a vitamin k antagonist or with a gamma -glutamyl carboxylase inhibitor for the therapy of androgen receptor positive cancer |
CN113598842A (zh) | 2015-06-03 | 2021-11-05 | 因塔西亚制药公司 | 植入物放置和移除系统 |
US10238625B2 (en) | 2015-08-07 | 2019-03-26 | Respivant Sciences Gmbh | Methods for the treatment of mast cell related disorders with mast cell stabilizers |
US10265296B2 (en) | 2015-08-07 | 2019-04-23 | Respivant Sciences Gmbh | Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders |
BR122020022602B1 (pt) | 2015-12-04 | 2024-03-05 | Mexichem Fluor S.A. De C.V. | Composição farmacêutica |
HUE056897T2 (hu) | 2015-12-09 | 2022-03-28 | Univ Wien Med | Monomaleimid-funkcionalizált platinavegyületek rákterápiához |
JP2019508383A (ja) | 2016-01-15 | 2019-03-28 | ウニベルジテート ハンブルグUniversitaet Hamburg | O−ラムノシル残基を有するフラボノイド型化合物 |
AU2017215189A1 (en) | 2016-02-01 | 2018-08-02 | Incarda Therapeutics, Inc. | Combining electronic monitoring with inhaled pharmacological therapy to manage cardiac arrhythmias including atrial fibrillation |
EP3416947A1 (en) | 2016-02-15 | 2018-12-26 | CeMM - Forschungszentrum für Molekulare Medizin GmbH | Taf1 inhibitors for the therapy of cancer |
EA201892190A1 (ru) | 2016-03-29 | 2019-04-30 | Янссен Байотек, Инк. | Лечение псориаза антителом к ил-12 и/или ил-23 с возрастанием интервала между введениями дозы |
WO2017178820A1 (en) | 2016-04-15 | 2017-10-19 | Oxford University Innovation Limited | Adenosine receptor modulators for the treatment of circadian rhythm disorders |
MX2018014016A (es) | 2016-05-16 | 2019-08-01 | Intarcia Therapeutics Inc | Polipéptidos selectivos del receptor de glucagón y métodos para utilizarlos. |
USD860451S1 (en) | 2016-06-02 | 2019-09-17 | Intarcia Therapeutics, Inc. | Implant removal tool |
USD840030S1 (en) | 2016-06-02 | 2019-02-05 | Intarcia Therapeutics, Inc. | Implant placement guide |
MX2019000641A (es) | 2016-07-15 | 2019-06-10 | Poseida Therapeutics Inc | Composiciones de mucina1-receptor de antigeno quimerico y metodos para su uso. |
WO2018014038A1 (en) | 2016-07-15 | 2018-01-18 | Poseida Therapeutics, Inc. | Chimeric antigen receptors and methods for use |
JP2019528320A (ja) | 2016-08-31 | 2019-10-10 | レシュピファント サイエンシス ゲゼルシャフト ミット ベシュレンクター ハフトゥングRespivant Sciences Gmbh | 特発性肺線維症による慢性咳の治療のためのクロモリン組成物 |
JP2019524865A (ja) | 2016-08-31 | 2019-09-05 | ザ ジェネラル ホスピタル コーポレイション | 神経変性疾患と関連する神経炎症におけるマクロファージ/ミクログリア |
CN116898804A (zh) | 2016-09-19 | 2023-10-20 | 墨西哥氟石股份公司 | 药物组合物 |
JP6781828B2 (ja) | 2016-09-19 | 2020-11-04 | メキシケム フロー エセ・ア・デ・セ・ヴェ | 医薬組成物 |
AU2017328907B2 (en) | 2016-09-19 | 2020-04-09 | Mexichem Fluor S.A. De C.V. | Pharmaceutical composition |
US11260052B2 (en) | 2016-09-19 | 2022-03-01 | Mexichem Fluor S.A. De C.V. | Pharmaceutical composition |
CA3037961A1 (en) | 2016-09-30 | 2018-04-05 | Janssen Biotech, Inc. | Safe and effective method of treating psoriasis with anti-il23 specific antibody |
EP3522983A4 (en) | 2016-10-07 | 2020-06-03 | Respivant Sciences GmbH | CROMOLYNE-BASED COMPOSITIONS FOR THE TREATMENT OF PULMONARY FIBROSIS |
WO2018087401A2 (en) | 2016-11-14 | 2018-05-17 | Cemm - Forschungszentrum Für Molekulare Medizin Gmbh | Combination of a brd4 inhibitor and an antifolate for the therapy of cancer |
MA46861A (fr) | 2016-11-16 | 2019-09-25 | Janssen Biotech Inc | Procédé de traitement du psoriasis avec un anticorps anti-il-23 spécifique |
EP3565580B1 (en) | 2017-01-03 | 2024-03-06 | i2o Therapeutics, Inc. | Continuous administration of exenatide and co-adminstration of acetaminophen, ethinylestradiol or levonorgestrel |
EP3621616A4 (en) | 2017-05-10 | 2021-01-13 | InCarda Therapeutics, Inc. | UNIT DOSE, AEROSOLS, KITS AND METHODS FOR TREATMENT OF HEART DISEASE BY PULMONAL ADMINISTRATION |
US20200368312A1 (en) | 2017-05-22 | 2020-11-26 | Insmed Incorporated | Glycopeptide derivative compounds and uses thereof |
CA3070386A1 (en) | 2017-07-20 | 2019-01-24 | Aztherapies, Inc. | Powdered formulations of cromolyn sodium and ibuprofen |
EP3679145A2 (en) | 2017-09-08 | 2020-07-15 | Poseida Therapeutics, Inc. | Compositions and methods for chimeric ligand receptor (clr)-mediated conditional gene expression |
TW201922780A (zh) | 2017-09-25 | 2019-06-16 | 美商健生生物科技公司 | 以抗il12/il23抗體治療狼瘡之安全且有效之方法 |
US11744967B2 (en) | 2017-09-26 | 2023-09-05 | Shin Nippon Biomedical Laboratories, Ltd. | Intranasal delivery devices |
US20210179591A1 (en) | 2017-12-05 | 2021-06-17 | Eth Zurich | New compounds for use as a therapeutically active substance and in particular for use in the treatment of tumors |
SG11202005750TA (en) | 2017-12-20 | 2020-07-29 | Poseida Therapeutics Inc | Vcar compositions and methods for use |
MA54132A (fr) | 2018-03-05 | 2022-04-27 | Janssen Biotech Inc | Méthodes de traitement de la maladie de crohn avec un anticorps spécifique anti-il23 |
US20210107993A1 (en) | 2018-03-07 | 2021-04-15 | Poseida Therapeutics, Inc. | Cartyrin compositions and methods for use |
EP3768378A4 (en) | 2018-03-22 | 2021-11-17 | InCarda Therapeutics, Inc. | INNOVATIVE METHOD OF SLOWING THE VENTRICULAR RATE |
CA3096146A1 (en) | 2018-04-06 | 2019-10-10 | Zilentin AG | Bumetanide derivatives for the therapy of hyperhidrosis |
WO2019193161A1 (en) | 2018-04-06 | 2019-10-10 | Universität Wien | Bumetanide derivatives for the therapy of stroke and other neurological diseases/disorders involving nkccs |
MA52590A (fr) | 2018-05-11 | 2021-03-17 | Janssen Biotech Inc | Méthodes de traitement de la dépression à l'aide d'anticorps il-23 |
US10414721B1 (en) | 2018-06-04 | 2019-09-17 | University Of Bern | Inhibitor of endocannabinoid cellular reuptake |
AU2019299347A1 (en) | 2018-07-02 | 2021-01-21 | Aztherapies, Inc. | Powdered formulations of cromolyn sodium and alpha-lactose |
JP2021530697A (ja) | 2018-07-18 | 2021-11-11 | ヤンセン バイオテツク,インコーポレーテツド | 抗il23特異的抗体で治療した後の持続応答予測因子 |
US10961307B2 (en) | 2018-09-24 | 2021-03-30 | Janssen Biotech, Inc. | Methods of treating moderately to severely active ulcerative colitis by administering an anti-IL12/IL23 antibody |
AU2019383017A1 (en) | 2018-11-20 | 2021-06-03 | Janssen Biotech, Inc. | Safe and effective method of treating psoriasis with anti-IL-23 specific antibody |
WO2020127200A1 (en) | 2018-12-17 | 2020-06-25 | Tolremo Therapeutics Ag | Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment, amelioration or prevention of cancer |
US20200197517A1 (en) | 2018-12-18 | 2020-06-25 | Janssen Biotech, Inc. | Safe and Effective Method of Treating Lupus with Anti-IL12/IL23 Antibody |
CA3125622C (en) | 2019-01-03 | 2023-09-26 | Aqua Yield Operations LLC | Pamam dendrimers for fertilizer delivery |
EP3938384A4 (en) | 2019-03-14 | 2022-12-28 | Janssen Biotech, Inc. | METHODS OF MANUFACTURING FOR PRODUCING ANTI-IL12/IL23 ANTIBODY COMPOSITIONS |
MA55383A (fr) | 2019-03-18 | 2022-01-26 | Janssen Biotech Inc | Méthode de traitement du psoriasis chez des sujets pédiatriques avec un anticorps anti-il12/il23 |
US11932585B2 (en) | 2019-04-12 | 2024-03-19 | Aqua Yield Operations LLC | Blended nanoparticle fertilizer delivery |
CN110051868A (zh) * | 2019-04-15 | 2019-07-26 | 宝盈联华(厦门)生物科技有限公司 | 一种带有硅碳岩、礌石粉的橱柜灭菌器 |
JP7404671B2 (ja) * | 2019-06-25 | 2023-12-26 | 株式会社リコー | 多孔質微粒子及びその製造方法、並びに医薬組成物 |
US11007185B2 (en) | 2019-08-01 | 2021-05-18 | Incarda Therapeutics, Inc. | Antiarrhythmic formulation |
WO2021064141A1 (en) | 2019-10-02 | 2021-04-08 | Tolremo Therapeutics Ag | Inhibitors of dual specificity tyrosine phosphorylation regulated kinase 1b |
WO2021064142A1 (en) | 2019-10-02 | 2021-04-08 | Tolremo Therapeutics Ag | Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment or amelioration of cancer |
WO2021074418A1 (en) | 2019-10-16 | 2021-04-22 | Cemm - Forschungszentrum Für Molekulare Medizin Gmbh | Carbazole-type cullin ring ubiquitin ligase compounds and uses thereof |
IL292153A (en) | 2019-10-16 | 2022-06-01 | Cemm Forschungszentrum Fur Molekulare Medizin Gmbh | Oxazole and thiazole choline ubiquitin ligase ring compounds and uses thereof |
WO2021211628A1 (en) | 2020-04-14 | 2021-10-21 | Poseida Therapeutics, Inc. | Compositions and methods for use in the treatment of cancer |
WO2021216547A1 (en) | 2020-04-20 | 2021-10-28 | Sorrento Therapeutics, Inc. | Pulmonary administration of ace2 polypeptides |
WO2021214588A1 (en) | 2020-04-21 | 2021-10-28 | Janssen Biotech, Inc. | Anti-tnf alpha agent for treating coronavirus infections |
WO2021214587A1 (en) | 2020-04-21 | 2021-10-28 | Janssen Biotech, Inc. | Anti-tnf alpha agent for treating viral infections |
WO2021260110A1 (en) | 2020-06-25 | 2021-12-30 | Tolremo Therapeutics Ag | Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment, amelioration or prevention of fibrotic disease |
EP3939578A1 (en) | 2020-07-13 | 2022-01-19 | Novaremed Ltd. | Compounds for treatment or prevention of an infection resulting from a coronavirus and/or a coronavirus-induced disease |
CN111700883B (zh) * | 2020-07-23 | 2021-04-06 | 深圳大佛药业股份有限公司 | 一种硫酸沙丁胺醇缓释型吸入制剂及其生产工艺 |
EP3964497A1 (en) | 2020-09-04 | 2022-03-09 | Friedrich-Alexander-Universität Erlangen-Nürnberg | Substituted vicinal diamine compounds and their use in the treatment, amelioration or prevention of pain |
US20230270669A1 (en) | 2020-09-04 | 2023-08-31 | Mexichem Fluor S.A. De C.V. | Pharmaceutical composition |
EP4229037A2 (en) | 2020-10-16 | 2023-08-23 | CeMM - Forschungszentrum für Molekulare Medizin GmbH | Heterocyclic cullin ring ubiquitin ligase compounds and uses thereof |
CN112495316B (zh) * | 2020-10-20 | 2021-11-19 | 大连理工大学 | 一种基于亚稳态乳液制备微纳米凝胶微球的方法 |
CN116546980A (zh) * | 2020-12-11 | 2023-08-04 | 江苏恒瑞医药股份有限公司 | 用于肺部递送的药物组合物 |
AU2022233792A1 (en) | 2021-03-12 | 2023-10-26 | Janssen Biotech, Inc. | Safe and effective method of treating psoriatic arthritis with anti-il23 specific antibody |
BR112023018400A2 (pt) | 2021-03-12 | 2023-12-12 | Janssen Biotech Inc | Método para tratamento de pacientes de artrite psoriática com resposta inadequada à terapia de tnf com anticorpo específico anti-il23 |
WO2022189662A1 (en) | 2021-03-12 | 2022-09-15 | Alvarius Pharmaceuticals Ltd. | Compositions and methods for treating addictions comprising 5-meo-dmt |
JP2024515061A (ja) | 2021-04-07 | 2024-04-04 | トルレモ・セラピューティクス・アクチェンゲゼルシャフト | 複素環誘導体、医薬組成物およびがんの治療または軽快におけるこれらの使用 |
CN117916260A (zh) | 2021-07-09 | 2024-04-19 | 詹森生物科技公司 | 用于制备抗il12/il23抗体组合物的制造方法 |
CA3236779A1 (en) | 2021-10-29 | 2023-05-04 | Janssen Biotech, Inc. | Methods of treating crohn's disease with anti-il23 specific antibody |
WO2023084488A1 (en) | 2021-11-15 | 2023-05-19 | Janssen Biotech, Inc. | Methods of treating crohn's disease with anti-il23 specific antibody |
US20230159633A1 (en) | 2021-11-23 | 2023-05-25 | Janssen Biotech, Inc. | Method of Treating Ulcerative Colitis with Anti-IL23 Specific Antibody |
US20230312703A1 (en) | 2022-03-30 | 2023-10-05 | Janssen Biotech, Inc. | Method of Treating Psoriasis with IL-23 Specific Antibody |
WO2023203172A1 (en) | 2022-04-20 | 2023-10-26 | Proxygen Gmbh | Heterocyclic cullin ring ubiquitin ligase compounds and uses thereof |
WO2023223265A1 (en) | 2022-05-18 | 2023-11-23 | Janssen Biotech, Inc. | Method for evaluating and treating psoriatic arthritis with il23 antibody |
CN115144310A (zh) * | 2022-07-01 | 2022-10-04 | 重庆交通大学 | 一种旋桨式絮凝沉降试验装置及方法 |
Family Cites Families (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1410588A (en) † | 1971-08-10 | 1975-10-22 | Fisons Ltd | Composition |
JPS5134879A (en) * | 1974-09-19 | 1976-03-24 | Eisai Co Ltd | Bishochukuryushinoseizoho |
US4147766A (en) † | 1976-06-09 | 1979-04-03 | Armour Pharmaceutical Company | Macrospherical particles of anti-perspirants |
DE3268533D1 (en) * | 1981-07-24 | 1986-02-27 | Fisons Plc | Inhalation drugs, methods for their production and pharmaceutical formulations containing them |
ATE93384T1 (de) * | 1983-11-14 | 1993-09-15 | Univ Kentucky Res Found | Poroese mikrokugeln zur arzneistoffabgabe sowie verfahren zu deren herstellung. |
US4963367A (en) * | 1984-04-27 | 1990-10-16 | Medaphore, Inc. | Drug delivery compositions and methods |
GB8502892D0 (en) * | 1985-02-05 | 1985-03-06 | Sterwin Ag | Aerosol composition |
WO1986006959A1 (en) * | 1985-05-22 | 1986-12-04 | Liposome Technology, Inc. | Liposome inhalation method and system |
US4950477A (en) † | 1988-08-23 | 1990-08-21 | Memorial Hospital For Cancer And Allied Dieseas | Method of preventing and treating pulmonary infection by fungi using aerosolized polyenes |
GB8828477D0 (en) * | 1988-12-06 | 1989-01-05 | Riker Laboratories Inc | Medical aerosol formulations |
DE69005800T2 (de) * | 1989-05-01 | 1994-05-19 | Alkermes Inc | Verfahren zur herstellung von kleinen partikeln von biologisch aktiven molekülen. |
US5733572A (en) * | 1989-12-22 | 1998-03-31 | Imarx Pharmaceutical Corp. | Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles |
US5585112A (en) * | 1989-12-22 | 1996-12-17 | Imarx Pharmaceutical Corp. | Method of preparing gas and gaseous precursor-filled microspheres |
JPH05507090A (ja) * | 1990-05-08 | 1993-10-14 | リポサーム テクノロジー インコーポレイテッド | 直接噴霧乾燥された薬剤/脂質粉末組成物 |
US5126123A (en) † | 1990-06-28 | 1992-06-30 | Glaxo, Inc. | Aerosol drug formulations |
US5230884A (en) † | 1990-09-11 | 1993-07-27 | University Of Wales College Of Cardiff | Aerosol formulations including proteins and peptides solubilized in reverse micelles and process for making the aerosol formulations |
US5304125A (en) † | 1990-10-05 | 1994-04-19 | The University Of North Carolina | Apparatus for administering solid particulate aerosols to the lungs |
US5616311A (en) * | 1991-01-15 | 1997-04-01 | Hemosphere, Inc. | Non-crosslinked protein particles for therapeutic and diagnostic use |
DK0495187T3 (da) * | 1991-01-15 | 1997-08-11 | Hemosphere Inc | Protein-nanomatricer og fremstillingsmetode. |
US5182097A (en) † | 1991-02-14 | 1993-01-26 | Virginia Commonwealth University | Formulations for delivery of drugs by metered dose inhalers with reduced or no chlorofluorocarbon content |
JP3507486B2 (ja) † | 1991-03-15 | 2004-03-15 | アムジエン・インコーポレーテツド | 顆粒球コロニー刺激因子の肺内投与 |
SE9101090D0 (sv) * | 1991-04-11 | 1991-04-11 | Astra Ab | Process for conditioning of water-soluble substances |
JPH05500229A (ja) * | 1991-04-12 | 1993-01-21 | 東レ株式会社 | 固体ポリペプチド微粒子のエアロゾル製剤とその製造方法 |
CA2111002C (en) * | 1991-06-10 | 2000-08-22 | Julianne Fassberg | Non-chlorofluorocarbon aerosol formulations |
WO1993011747A1 (en) * | 1991-12-18 | 1993-06-24 | Minnesota Mining And Manufacturing Company | Suspension aerosol formulations |
US5376359A (en) † | 1992-07-07 | 1994-12-27 | Glaxo, Inc. | Method of stabilizing aerosol formulations |
US6582728B1 (en) * | 1992-07-08 | 2003-06-24 | Inhale Therapeutic Systems, Inc. | Spray drying of macromolecules to produce inhaleable dry powders |
US5354934A (en) † | 1993-02-04 | 1994-10-11 | Amgen Inc. | Pulmonary administration of erythropoietin |
DE4323636A1 (de) * | 1993-07-15 | 1995-01-19 | Hoechst Ag | Arzneistoffzubereitungen aus umhüllten, schwerstwasserlöslichen Arzneistoffen für Inhalationsarzneiformen und Verfahren zu ihrer Herstellung |
US5798091A (en) † | 1993-07-30 | 1998-08-25 | Alliance Pharmaceutical Corp. | Stabilized gas emulsion containing phospholipid for ultrasound contrast enhancement |
JP3559849B2 (ja) * | 1993-07-30 | 2004-09-02 | アイエムシーオーアール ファーマシューティカル カンパニー | 超音波技術のための安定化された微小気泡組成物 |
EP0655237A1 (de) * | 1993-11-27 | 1995-05-31 | Hoechst Aktiengesellschaft | Medizinische Aerosolformulierung |
US5540909A (en) * | 1994-09-28 | 1996-07-30 | Alliance Pharmaceutical Corp. | Harmonic ultrasound imaging with microbubbles |
HUT77373A (hu) † | 1994-09-29 | 1998-03-30 | Andaris Limited | Porlasztva szárított mikrorészecskék gyógyszerészeti hordozóként |
GB9423419D0 (en) * | 1994-11-19 | 1995-01-11 | Andaris Ltd | Preparation of hollow microcapsules |
US6524557B1 (en) * | 1994-12-22 | 2003-02-25 | Astrazeneca Ab | Aerosol formulations of peptides and proteins |
HUT77775A (hu) * | 1994-12-22 | 1998-08-28 | Astra Aktiebolag | Aeroszolformák |
JP3708553B2 (ja) * | 1995-04-14 | 2005-10-19 | ネクター セラピューティクス | 向上した分散性を有する粉末型薬理組成物 |
EP0831932B1 (en) † | 1995-06-07 | 2004-05-06 | Imarx Pharmaceutical Corp. | Novel targeted compositions for diagnostic and therapeutic use |
US5654007A (en) * | 1995-06-07 | 1997-08-05 | Inhale Therapeutic Systems | Methods and system for processing dispersible fine powders |
US6041777A (en) * | 1995-12-01 | 2000-03-28 | Alliance Pharmaceutical Corp. | Methods and apparatus for closed-circuit ventilation therapy |
GB9606677D0 (en) * | 1996-03-29 | 1996-06-05 | Glaxo Wellcome Inc | Process and device |
EP0954282B1 (en) † | 1997-01-16 | 2005-01-19 | Massachusetts Institute Of Technology | Preparation of particles for inhalation |
AU756693B2 (en) * | 1997-09-29 | 2003-01-23 | Novartis Ag | Stabilized bioactive preparations and methods of use |
-
1998
- 1998-09-29 AU AU96770/98A patent/AU756693B2/en not_active Ceased
- 1998-09-29 EA EA200000375A patent/EA002562B1/ru not_active IP Right Cessation
- 1998-09-29 ES ES98950826T patent/ES2205560T5/es not_active Expired - Lifetime
- 1998-09-29 KR KR1020007003368A patent/KR100599634B1/ko not_active IP Right Cessation
- 1998-09-29 ES ES98954933T patent/ES2195415T3/es not_active Expired - Lifetime
- 1998-09-29 PL PL98339732A patent/PL195212B1/pl unknown
- 1998-09-29 CZ CZ20001115A patent/CZ300758B6/cs not_active IP Right Cessation
- 1998-09-29 JP JP2000513560A patent/JP2003525842A/ja not_active Withdrawn
- 1998-09-29 WO PCT/US1998/020615 patent/WO1999016422A1/en active IP Right Grant
- 1998-09-29 JP JP2000513558A patent/JP2001517692A/ja active Pending
- 1998-09-29 CA CA002304973A patent/CA2304973C/en not_active Expired - Fee Related
- 1998-09-29 KR KR1020007003401A patent/KR100575070B1/ko not_active IP Right Cessation
- 1998-09-29 AT AT98953220T patent/ATE238035T1/de active
- 1998-09-29 WO PCT/US1998/020602 patent/WO1999016419A1/en active Application Filing
- 1998-09-29 PT PT98953220T patent/PT1019022E/pt unknown
- 1998-09-29 DE DE69813853T patent/DE69813853T3/de not_active Expired - Lifetime
- 1998-09-29 AU AU11857/99A patent/AU750567B2/en not_active Ceased
- 1998-09-29 NZ NZ503464A patent/NZ503464A/en not_active IP Right Cessation
- 1998-09-29 ES ES98953220T patent/ES2195408T5/es not_active Expired - Lifetime
- 1998-09-29 EP EP98950826A patent/EP1019021B2/en not_active Expired - Lifetime
- 1998-09-29 AU AU96772/98A patent/AU757153B2/en not_active Expired
- 1998-09-29 AT AT98950826T patent/ATE248583T1/de not_active IP Right Cessation
- 1998-09-29 BR BR9812693-8A patent/BR9812693A/pt not_active Application Discontinuation
- 1998-09-29 ME MEP-41/08A patent/MEP4108A/xx unknown
- 1998-09-29 CN CNB98809603XA patent/CN1169520C/zh not_active Expired - Lifetime
- 1998-09-29 EP EP98953220A patent/EP1019022B2/en not_active Expired - Lifetime
- 1998-09-29 RS YUP-183/00A patent/RS50182B/sr unknown
- 1998-09-29 KR KR1020007003367A patent/KR100589926B1/ko not_active IP Right Cessation
- 1998-09-29 EP EP98950824A patent/EP1019020A1/en not_active Withdrawn
- 1998-09-29 DE DE69814428T patent/DE69814428T2/de not_active Expired - Lifetime
- 1998-09-29 SK SK449-2000A patent/SK285068B6/sk not_active IP Right Cessation
- 1998-09-29 TR TR2000/00819T patent/TR200000819T2/xx unknown
- 1998-09-29 EA EA200200036A patent/EA003665B1/ru not_active IP Right Cessation
- 1998-09-29 CA CA002304820A patent/CA2304820C/en not_active Expired - Fee Related
- 1998-09-29 EE EEP200000194A patent/EE04628B1/xx unknown
- 1998-09-29 AU AU10644/99A patent/AU757337C/en not_active Expired
- 1998-09-29 IL IL13512698A patent/IL135126A0/xx active IP Right Grant
- 1998-09-29 JP JP2000513557A patent/JP5372306B2/ja not_active Expired - Lifetime
- 1998-09-29 EP EP98954933A patent/EP1019023B1/en not_active Expired - Lifetime
- 1998-09-29 JP JP2000513559A patent/JP4526702B2/ja not_active Expired - Fee Related
- 1998-09-29 KR KR1020007003416A patent/KR100572171B1/ko not_active IP Right Cessation
- 1998-09-29 CA CA002304819A patent/CA2304819C/en not_active Expired - Lifetime
- 1998-09-29 AT AT98954933T patent/ATE239447T1/de not_active IP Right Cessation
- 1998-09-29 CA CA002304975A patent/CA2304975C/en not_active Expired - Lifetime
- 1998-09-29 DK DK98950826.2T patent/DK1019021T4/da active
- 1998-09-29 WO PCT/US1998/020613 patent/WO1999016421A1/en active IP Right Grant
- 1998-09-29 DK DK98953220.5T patent/DK1019022T4/da active
-
2000
- 2000-03-16 IL IL135126A patent/IL135126A/en not_active IP Right Cessation
- 2000-03-17 BG BG104253A patent/BG64816B1/bg unknown
- 2000-03-24 IS IS5415A patent/IS2154B/is unknown
- 2000-03-28 HR HR20000175A patent/HRP20000175B1/xx not_active IP Right Cessation
- 2000-03-28 NO NO20001618A patent/NO340149B1/no not_active IP Right Cessation
-
2001
- 2001-01-19 HK HK01100524A patent/HK1031680A1/xx not_active IP Right Cessation
-
2009
- 2009-12-01 JP JP2009274003A patent/JP2010047615A/ja not_active Withdrawn
-
2011
- 2011-03-16 JP JP2011058608A patent/JP5739197B2/ja not_active Expired - Lifetime
-
2013
- 2013-07-08 JP JP2013142326A patent/JP6100114B2/ja not_active Expired - Lifetime
- 2013-07-11 JP JP2013145351A patent/JP2013216688A/ja not_active Withdrawn
-
2014
- 2014-06-24 JP JP2014128936A patent/JP6078498B2/ja not_active Expired - Lifetime
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
YU18300A (sh) | Perforisane mikročestice i postupci za njihovu primenu | |
LV12586A (en) | Aerosolized active agent delivery | |
YU26101A (sh) | Oslobađanje aerosoliziranog aktivnog agensa modulisane otpornosti protoka | |
HK1025270A1 (en) | Disposable inhaler | |
WO2001095874A3 (en) | Highly efficient delivery of a large therapeutic mass aerosol | |
SI1158958T1 (sl) | Izboljĺ ani praĺ kasti farmacevtski sestavki za inhalacijo | |
GB9606677D0 (en) | Process and device | |
NZ332669A (en) | A dry power inhalation system which is flow rate independent | |
ATE382386T1 (de) | Multidosis-trockenpulverinhalator mit pulverreservoir | |
JO2430B1 (en) | Pharmaceutical formulas for dry powder inhalations in the form of solid pellets | |
IS1768B (is) | Lyfjablanda til innöndunar sem inniheldur insúlín | |
MY129384A (en) | "pharmaceutical formulations for dry powder inhalers in the form of hard-pellets" | |
NZ535284A (en) | Microparticles of glycopyrrolate for the treatment of respiratory diseases | |
WO2007042822A3 (en) | Unit dose dry powder inhaler | |
GEP20043258B (en) | Systems and Methods for Aerosolizing Pharmaceutical Formulations | |
EP0839544A3 (en) | Inhalers | |
WO2006008517A3 (en) | Use of dry powder compositions for pulmonary delivery | |
AU2001252306A1 (en) | Powder inhaler | |
IL149027A0 (en) | Medicament delivery device with moisture resistant coating | |
ME00003B (me) | Perforisane mikročestice i postupci za njihovu primjenu | |
GEP20022782B (en) | Perforated Microparticles, Methods of Their Production, Their Use for Production of Aerosol Medikaments | |
NZ329747A (en) | Method of respiratory delivery of insulin as a dry powder | |
GB2431883A (en) | Rapid mixing inhaler |